- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07722741
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC (IMPACT31)
IMPACT31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to undergo definitive resection, have demonstrated laboratory, radiographic and/or pathologic high-risk criteria for recurrence (described under eligibility), have no evidence of disease (NED) as per MRI approximately 28 days post resection, and are able to provide a tissue sample for personalized neoantigen DNA vaccine development.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Joann Peters, MHA
- Telefonnummer: 434-825-2551
- E-post: peters@geneostx.com
Studieorter
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Har inte rekryterat ännu
- Emory University
-
Kontakt:
- Principal Investigator, MD
- Telefonnummer: 404-251-1278
- E-post: kathleen.marie.coleman@emory.edu
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70112
- Rekrytering
- Louisiana State University Health Sciences Center
-
Kontakt:
- Principal Investigator, MD
- Telefonnummer: 504-568-4750
- E-post: omoave@lsuhsc.edu
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Rekrytering
- Johns Hopkins University
-
Kontakt:
- Principal Investigator, MD
- Telefonnummer: 410-955-8893
- E-post: GIClinicalTrials@jh.edu
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- Har inte rekryterat ännu
- University of Michigan
-
Kontakt:
- Principal Investigator, MD
- Telefonnummer: 734-936-8643
- E-post: ndparikh@med.umich.edu
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Rekrytering
- Icahn School of Medicine at Mount Sinai
-
Kontakt:
- Principal Investigator, MD
- Telefonnummer: 212-241-7840
- E-post: denise.rodriguez3@mssm.edu
-
New York, New York, Förenta staterna, 10027
- Har inte rekryterat ännu
- New York Presbyterian Hospital-Columbia University Irving Medical Center
-
Kontakt:
- Principal Investigator, MD
- Telefonnummer: 212-342-5162
- E-post: Cancerclinicaltrials@cumc.columbia.edu
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Har inte rekryterat ännu
- MD Anderson Cancer Center
-
Kontakt:
- Principal Investigator, MD
- Telefonnummer: 713-792-2828
- E-post: GIClinicalTrials@mdanderson.org
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98109
- Har inte rekryterat ännu
- Fred Hutchinson Cancer Center
-
Kontakt:
- Principal Investigator, MD
- Telefonnummer: 206-667-1392
- E-post: giresearch@fredhutch.org
-
-
-
-
-
Auckland, Nya Zeeland, 1023
- Rekrytering
- Auckland City Hospital (Te Toka Tumai)
-
Kontakt:
- Principal Investigator, MD
- Telefonnummer: 22932 64 0800 488 434
- E-post: LiverResearchUnit@adhb.govt.nz
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Written informed consent
- ≥18 years of age
- Histologically or cytologically confirmed diagnosis of HCC (not accepted: fibrolamellar, sarcomatoid, mixed cholangiocarcinoma)
- Child-Pugh Class A liver score
- Documented virology status of hepatitis
- Availability of a representative post-resection tumor tissue sample
- ECOG performance status of 0 or 1
- Adequate organ function
- Women of childbearing potential (WOCBP) and men must be willing to use an adequate method of contraception
Exclusion Criteria:
- Is currently participating in and receiving study drug or has participated in a study of an investigational agent and received study drug or used an investigation device, within 4 weeks to baseline
- Evidence of residual, recurrent, or metastatic disease at randomization
- Active or history of autoimmune disease or immune deficiency
- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
- Diagnosed additional malignancy within 5 years prior to baseline, except for: (a) non-invasive carcinomas subject to successful curative treatment in the opinion of the investigator which require no further therapy and (b) other malignancies for which subjects have undergone potentially curative therapy and have been considered disease free for at least 3 years prior to screening.
- Active infection requiring systemic therapy
- Is pregnant, breastfeeding or expecting to conceive or father children within the study's projected duration
- History of human immunodeficiency virus (HIV) (HIV I/II antibodies).
- Co-infection with HBV and hepatitis D viral infection
- Co-infection with HBV and HCV
- Has received a live vaccine within 30 days of planned start of study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Personalized Immunotherapy for Cancer:
GNOS-PV02 + INO-9012 ID followed by electroporation every 3 weeks for 4 doses, then every 9 weeks (Q9W) until week 104, then every 12 weeks (Q12W) until week 260 followed by 3 years follow-up survival |
delivered by intradermal injection and electroporation GNOS-PV02 + INO-9012 ID followed by electroporation cytokine interleukin-12 (IL-12), a vaccine adjuvant |
|
Inget ingripande: Standard of Care
Active Surveillance for 5 years or until recurrence, plus 3 years follow-up survival. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Recurrence-free survival
Tidsram: Up to 5 years
|
RFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary HCC, as assessed by the investigator, or death due to any cause, whichever occurs first. |
Up to 5 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of treatment emergent adverse events (safety and tolerability)
Tidsram: Up to 5 years
|
Summary adverse events according to CTCAE 6.0 |
Up to 5 years
|
|
Time to extra-hepatic spread or macro-vascular invasion
Tidsram: Up to 5 years
|
Time to extra-hepatic spread or macro-vascular invasion (TTEHS/MVI) |
Up to 5 years
|
|
Overall survival
Tidsram: Up to 5 years on study + 3 years follow up
|
OS is defined as time from randomization to death of any cause |
Up to 5 years on study + 3 years follow up
|
|
RFS rate at 12, 18 and 24 months as assessed by the investigator
Tidsram: Randomization up to 12 months, 18 and 24 months
|
The proportion of patients who remain free from disease recurrence after treatment over a specified period |
Randomization up to 12 months, 18 and 24 months
|
|
RFS rate at 12, 18 and 24 months as assessed by the BIRC
Tidsram: Randomization up to 12 months, 18 months and 24 months
|
The proportion of patients who remain free from disease recurrence after treatment over a specified period |
Randomization up to 12 months, 18 months and 24 months
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- GT-31
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
At the time of registration, the sponsor has not yet determined whether de-identified individual participant data collected during the study will be shared. A decision regarding data sharing will be made following study completion and in accordance with sponsor policies, applicable regulations, and ethical considerations.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .